$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Detailed explanation of Ixazomib (Enleri) onset time and treatment course observation recommendations
2026-02-01 22:25:32
Check Details
Analysis of indications and clinical application scope of rubitin/rubicatin (Zanbiga)
2026-02-01 22:25:32
Check Details
The latest research progress and future clinical application prospects of Pimitespib
2026-02-01 22:25:32
Check Details
Afatinib (Gitairin) drug interactions and precautions for co-administration
2026-02-01 22:25:32
Check Details
Analysis of patients’ real medication experience and effect feedback of DaliRasen (Keweike)
2026-02-01 22:25:32
Check Details
Comparative analysis of the efficacy and safety of Lynparza and Pamiparib
2026-02-01 22:25:32
Check Details
Venetoclax/Venetoclax (Vekela) contraindications and instructions for those who should take it with caution
2026-02-01 22:25:32
Check Details
Possible drug resistance to Asnib/Aximinib (Sinbel) and treatment options for worsening
2026-02-01 22:25:32
Check Details
Detailed description of the storage conditions and drug preservation methods of Ritexitinib (Lefenox)
2026-02-01 22:25:32
Check Details
Comprehensive interpretation of the indications and clinical scope of sparsentan (sparsentan)
2026-02-01 22:25:32
Check Details
Ixazomib (Ixazomib) foreign generic drug prices and purchasing reference information
2026-02-01 22:25:32
Check Details
Rubitin/Rubicatin (Zanbega) Medication Guide and Safe Medication Operation Suggestions
2026-02-01 22:25:32
Check Details
1
2
...
2243
2244
2245
2246
2247
2248
2249
...
10240
10241
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): Indications, Dosing, Safety and the Next-Gen KRAS G12C Landscape
2
Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring
3
Pirtobrutinib and Risks of Atrial Fibrillation and Bleeding: Mechanism, Data Interpretation and Monitoring
4
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
5
Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen
6
Ponatinib in the PACE Phase II Trial: Response Data in Resistant CML and Ph+ ALL
7
Selumetinib for NF1-Related Plexiform Neurofibromas: Time to Response and Response Assessment
8
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
9
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
10
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
11
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
12
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment